Exhibit 10.1

 

Amendment No. 1 to SHARE PURCHASE AGREEMENT

 

This Amendment No. 1 to Share Purchase Agreement (this “Amendment”) is effective
as of April 27, 2018 by and among TNK Therapeutics, Inc., a Delaware corporation
(the “Purchaser”), Sorrento Therapeutics, Inc., a Delaware corporation
(“Sorrento”), and Dayspring Ventures Limited, a private limited company
registered in Jersey under company number 75238 with address at 4 Bond Street,
St Helier, Jersey JE2 3NP, as representative (the “Shareholders’
Representative”) of the shareholders (the “Shareholders”) of Virttu Biologics
Limited (the “Company”).

 

Recitals

 

Whereas, the Purchaser, Sorrento, the Shareholders and the Shareholders’
Representative are parties to that certain Share Purchase Agreement, dated as of
April 27, 2017, pursuant to which, among other things, the Shareholders sold to
the Purchaser and the Purchaser purchased from the Shareholders all of the
issued ordinary shares of 0.1p each in the capital of the Company (the “Share
Purchase Agreement”);

 

Whereas, pursuant to Section 10.3 of the Share Purchase Agreement, the Share
Purchase Agreement may not be amended, modified, altered or supplemented except
by written agreement between the Purchaser and the Shareholders’ Representative,
provided that the provisions of Sections 1.2(a), 1.4(b), 1.6, 1.7, 6.6, 6.8, 7.4
and 8.5(a) and Articles V and X thereof may not be amended without the consent
of Sorrento;

 

Whereas, the Purchaser, Sorrento and the Shareholders’ Representative
acknowledge and agree that a Qualified Financing has not occurred and will not
occur; and

 

Whereas, the Purchaser, Sorrento and the Shareholders’ Representative wish to
amend the Share Purchase Agreement, including portions of Sections 1.4(b) and
8.5(a) thereof, to make certain modifications to the consideration payable to
the Shareholders on the Financing Due Date in the event a Qualified Financing
does not occur on the terms set forth herein.

 

Now Therefore, in consideration of the mutual covenants and agreements contained
herein, and with reference to the above recitals, the parties hereby agree as
follows:

 

ARTICLE 1
AMENDMENTS

 

1.1 Amendment and Restatement of Section 1.4(b). Section 1.4(b) of the Share
Purchase Agreement is hereby amended and restated in its entirety to read as
follows:

 

“(b) In the event a Qualified Financing does not occur, then (i) subject to
Section 1.7 and Section 8.5(a), on the Financing Due Date, Sorrento shall issue
the Contingency Shares, free and clear of all Liens, and promptly thereafter
deliver to the Shareholders’ Representative (for distribution to the
Shareholders) the book entry statements representing the Contingency Shares in
the name of each Shareholder, in each case, for such number of shares of
Sorrento Common Stock as is equal to the product of the total number of
Contingency Shares multiplied by the quotient obtained by dividing (A) the total
number of Shares owned by such Shareholder as of immediately prior to the
Closing by (B) the total number of Shares outstanding as of immediately prior to
the Closing, and (ii) subject to Section 8.5(a), on or before June 27, 2018,
Sorrento shall pay the Contingency Cash by wire transfer of immediately
available funds to the account designated by the Shareholders’ Representative in
writing (for distribution to the Shareholders), in each case, for such amount as
is equal to the product of the total amount of Contingency Cash multiplied by
the quotient obtained by dividing (A) the total number of Shares owned by such
Shareholder as of immediately prior to the Closing by (B) the total number of
Shares outstanding as of immediately prior to the Closing.”

 

 

 

 

1.2 Amendment and Restatement of Section 6.8(c). Section 6.8(c) of the Share
Purchase Agreement is hereby amended and restated in its entirety to read as
follows:

 

“(c) The Shareholders have agreed that: (i) in the event a Qualified Financing
occurs, (A) upon issuance of the Non-Escrow Shares, 6% of the Non-Escrow Shares
deliverable to the Shareholders’ Representative for distribution to the
Shareholders (net of certain deductions as specified in the Staff Incentive
Scheme Rules) shall be held by the Shareholders’ Representative for the purposes
of the Staff Incentive Scheme (the “Non-Escrow Incentive Shares”), (B) upon
release of the Escrow Shares from escrow pursuant to the Escrow Agreement, 6% of
the Escrow Shares deliverable to the Shareholders’ Representative for
distribution to the Shareholders (net of certain deductions as specified in the
Staff Incentive Scheme Rules) shall be held by the Shareholders’ Representative
for the purposes of the Staff Incentive Scheme (the “Escrow Incentive Shares”);
and (ii) in the event a Qualified Financing does not occur, (A) upon issuance of
the Contingency Shares, 6% of the Contingency Shares deliverable to the
Shareholders’ Representative for distribution to the Shareholders (net of
certain deductions as specified in the Staff Incentive Scheme Rules) shall be
held by the Shareholders’ Representative for the purposes of the Staff Incentive
Scheme (the “Contingency Incentive Shares” and, together with the Closing
Incentive Shares, the Non-Escrow Incentive Shares and the Escrow Incentive
Shares, the “Incentive Shares”), and (B) upon the payment of the Contingency
Cash, 6% of the Contingency Cash deliverable to the Shareholders’ Representative
for distribution to the Shareholders (net of certain deductions as specified in
the Staff Incentive Scheme Rules) shall be held by the Shareholders’
Representative for the purposes of the Staff Incentive Scheme (the “Contingency
Incentive Cash”). For the avoidance of doubt, unless the Closing Incentive
Shares, Non-Escrow Incentive Shares, Escrow Incentive Shares or Contingency
Incentive Shares have been sold by the Shareholders’ Representative in
accordance with Section 6.8(d), such shares remain subject to the offset
mechanism in Section 8.5(a) to satisfy any Loss for which the Shareholders may
be liable under Article VIII.”

 

1.3 Amendment and Restatement of Section 6.8(d). Section 6.8(d) of the Share
Purchase Agreement is hereby amended and restated in its entirety to read as
follows:

 

2 

 

 

“(d) Once any Incentive Shares are free from any restrictions on marketability,
the Shareholders’ Representative will sell those Incentive Shares and the
proceeds of sale of each category of Incentive Shares shall be a bonus pool
available under the Staff Incentive Scheme (together the “Bonus Pools” and each
a “Bonus Pool”); provided, however, that the Contingency Incentive Cash shall be
included in the Bonus Pool resulting from the sale of the Contingency Incentive
Shares.”

 

1.4 Amendment to Section 8.1(a)(viii). The phrase “, the Contingency Cash” is
hereby inserted after the words “the Contingency Shares” in Section 8.1(a)(viii)
of the Share Purchase Agreement.

 

1.5 Amendment and Restatement Section 8.5(a)(x). Section 8.5(a)(x) of the Share
Purchase Agreement is hereby amended and restated in its entirety to read as
follows:

 

“(x) by offsetting such Losses against the amount of the Non-Escrow Shares,
Contingency Shares or Contingency Cash to be delivered to the Shareholders’
Representative for the benefit of such Indemnifying Party, provided, however,
that if an Indemnified Party in good faith has given written notice of a
Third-Party Claim containing a claim which has not been resolved in full prior
to the date on which the Purchaser would otherwise be required to procure the
issue of the Contingency Shares or payment of the Contingency Cash, Sorrento
shall not be required to issue an amount of Contingency Shares or pay an amount
of Contingency Cash equal to the amount described in each such written notice of
a Third-Party Claim, up to the total number of Contingency Shares and the total
amount of the Contingency Cash, until such resolution has taken place, whereupon
Sorrento shall issue an amount of Contingency Shares or pay an amount of
Contingency Cash equal to the amount of the claim not resolved in the
Indemnified Party’s favor,”

 

1.6 Amendment to Exhibit A. Exhibit A to the Share Purchase Agreement is hereby
amended by adding a new defined term “Contingency Cash” between the defined
terms “Confidential Information” and “Contingency Shares”, which shall read as
follows:

 

““Contingency Cash” means such amount of cash in United States Dollars as is
equal to 40% of the Estimated Purchase Price.”

 

1.7 Amendment to Definition of “Aggregate Consideration”. The phrase “, the
Contingency Cash” is hereby inserted after the words “the Contingency Shares” in
the definition of “Aggregate Consideration” set forth in Exhibit A to the Share
Purchase Agreement.

 

1.8 Amendment to Definition of “Contingency Shares”. The reference to “80%” in
the definition of “Contingency Shares” set forth in Exhibit A to the Share
Purchase Agreement is hereby deleted and replaced with “40%”.

 

1.9 Amendment to Definition of “Realized Purchase Price”. Section (c)(ii) of the
definition of “Realized Purchase Price” set forth in Exhibit A to the Share
Purchase Agreement is hereby deleted and replaced to read in its entirety as
follows:

 

“if after the Financing Due Date but a Qualified Financing has not occurred, in
respect of any Losses which are offset against the Contingency Shares, the
product obtained by multiplying (x) the number of Contingency Shares issued
pursuant to Section 1.4(b) by (y) the closing price per share of the Sorrento
Common Stock, as reported on the Nasdaq Capital Market as of the time at which
such shares of Sorrento Common Stock have been issued and are freely tradeable
plus an amount equal to the Contingency Cash; plus”

 

3 

 

 

ARTICLE 2
GENERAL PROVISIONS

 

2.1 Definitions. Capitalized terms in this Amendment but not otherwise defined
in this Amendment shall have the meanings set forth in the Share Purchase
Agreement.

 

2.2 Recitals. The Recitals shall be deemed to form part of this Agreement and
are binding on the parties hereto.

 

2.3 Continuing Effectiveness. Except as modified by this Amendment, the Share
Purchase Agreement shall remain in full force and effect and no party by virtue
of entering into this Amendment is waiving any rights it has under the Share
Purchase Agreement, and once this Amendment is executed by the parties hereto,
all references in the Share Purchase Agreement to “the Agreement” or “this
Agreement,” as applicable, shall refer to the Share Purchase Agreement as
modified by this Amendment.

 

2.4 Successors and Assigns. No party to this Amendment may assign any of its
rights or delegate any of its obligations under this Amendment without the prior
written consent of the other parties to this Amendment. Subject to the preceding
sentence, this Amendment shall apply to, be binding in all respects upon and
inure to the benefit of the successors and permitted assigns of the parties to
this Amendment.

 

2.5 Governing Law; Venue. This Amendment, the relationship of the parties hereto
and any claims or disputes arising under or relating to this Amendment shall be
governed by and construed in accordance with Section 10.6 of the Share Purchase
Agreement.

 

2.6 Execution of Amendment; Counterparts; Electronic Signatures.

 

(a) This Amendment may be executed in several counterparts, each of which shall
be deemed an original and all of which, when taken together, shall constitute
one and the same instrument, and shall become effective when counterparts have
been signed by each of the parties to this Amendment and delivered to the other
parties to this Amendment; it being understood that all parties to this
Amendment need not sign the same counterparts.

 

(b) This Amendment and any amendments to this Amendment may be executed in one
or more counterparts, each of which shall be enforceable against the parties to
this Amendment that execute such counterparts, and all of which together shall
constitute one and the same instrument. Facsimile and “.pdf” copies of signed
signature pages shall be deemed binding originals and no party to this Amendment
shall raise the use of facsimile machine or electronic transmission in “.pdf” as
a defense to the formation of a contract.

 

4 

 

 

In Witness Whereof, the parties have duly caused this Amendment No. 1 to Share
Purchase Agreement to be executed as of the day and year first above written.

 

THE PURCHASER   SHAREHOLDERS’ REPRESENTATIVE TNK Therapeutics, Inc.   Dayspring
Ventures Limited                     By: /s/ Henry Ji, Ph.D.   By: /s/ Daniel
Young Name: Henry Ji, Ph.D.   Name: Daniel Young Title: Chief Executive Officer
  Title: Director           SORRENTO       Sorrento Therapeutics, Inc.          
            By: /s/ Henry Ji, Ph.D.       Name: Henry Ji, Ph.D.      

Title: Chairman of the Board, President and

Chief Executive Officer

     

  

[Signature Page to Amendment No. 1 to Share Purchase Agreement]